Scientists hunt for Cancer's 'Weak Spot' to target immunotherapy
NCT ID NCT04957615
Summary
This study aims to identify biological markers in tumors that can predict which patients with advanced solid cancers will respond to immunotherapy. Researchers will treat 16 patients with the immunotherapy drug nivolumab and analyze their tumor tissue and blood samples. The goal is to learn if specific genetic mutations and protein levels can help doctors better match patients with effective treatments.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC MALIGNANT SOLID NEOPLASM are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.